Colgate Q2 FY27: revenue +12% YoY, PAT +4% as A&P jumps 40%, margins compress ~290bps
PAT +4.29% YoY · revenue +12.26% · margins compressing
₹1,705.79 Cr
+12.26% YoY
₹341.57 Cr
+4.29% YoY
19.77%
-1.6pp YoY
₹12.56
Colgate-Palmolive India's standalone Q2 FY27 (quarter ended September 30, 2026) revenue from operations came in at ₹1,705.79 Cr, up 12.3% YoY and 6.4% QoQ — a second straight quarter of double-digit top-line growth after Q1 FY27's 11.8%. But profit growth badly lagged: PAT of ₹341.57 Cr (EPS ₹12.56) rose just 4.3% YoY and actually slipped 0.4% QoQ from ₹343.08 Cr, with no exceptional items in either the current or year-ago quarter to distort the comparison — this is a genuine, operating-level growth-to-profit gap, not a base-effect or one-off artifact.
Q2 FY-2027 vs prior quarters
The gap sits squarely in margins: net profit margin fell to 19.8% of total income from 21.3% a year ago and 21.1% last quarter (a ~150bps YoY compression), while operating margin (EBITDA/revenue-from-operations) eased to roughly 27.8% from ~30.6% YoY and ~29.9% QoQ. The driver is advertising: A&P spend jumped 39.9% YoY and 25.0% QoQ to ₹314.82 Cr, taking A&P intensity to ~18.5% of revenue — above the ~15.8% level (up from 12-13%) management flagged on the August 2026 concall as the new normal for absorbing premiumisation-led brand investment. Employee costs also rose a faster 15.1% YoY, adding to the squeeze, while cost of materials grew a more moderate 9.2% YoY.
The stock went into the print at ₹1,685, down 10.9% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management targets sustained double-digit growth via balanced volume/price/mix with upward bias on premiumisation spend. Gross margins to remain 'in range'; EBITDA to absorb higher A&P (15.8%, up from 12-13%). No numeric FY27 revenue or PAT targets provided.
— This quarter: met
Against management's own prior guidance — sustained double-digit growth via volume/price/mix, margins absorbing higher A&P — this quarter is a clean match: growth delivered, and A&P ran even hotter than the 15.8% marker, so the compression reflects the plan playing out rather than a miss. No formal numeric consensus for this specific quarter turned up in public previews, so vsStreet is marked unknown; the broader brokerage tone (Goldman Sachs and Citi have held Sell ratings through 2026) has flagged exactly these margin and competitive-intensity concerns. It's also worth noting the YoY base is soft: Q2 FY26 PAT itself had fallen 17.1% YoY on GST-transition distributor disruption, so this year's +4.3% YoY sits on a depressed prior-year print. Alongside the results, the board declared a first interim dividend of ₹24/share (₹652.77 Cr aggregate, record date November 2, 2026), and separately the company saw a marketing leadership change — EVP-Marketing Gunjit Jain resigns effective November 30, succeeded by Akash Parekh from December 1 — landing just as A&P investment is being stepped up. No standalone press-release commentary from management was available in the filing to cross-check against the numbers.
W1
A&P intensity trajectory — guided to ~15.8% of revenue (from 12-13%); actual hit ~18.5% this quarter — watch whether Q3 FY27 holds near this level or normalizes down.
W2
Whether double-digit revenue growth (12.3% this quarter, 11.8% in Q1 FY27) sustains into H2 FY27 as the base normalizes from last year's GST-disruption-hit Q2 FY26.
W3
Leadership transition — new EVP-Marketing Akash Parekh takes over December 1, 2026, and MD&CEO Manish Anandani's formal appointment goes to shareholder postal ballot (cut-off October 23, 2026).
Standalone only — company has no subsidiary/JV (Note 7); single reportable segment 'Personal Care' so no segment breakout (Note 6); source figures in ₹ Lakh converted to Crore (÷100); no exceptional items this quarter or year-ago quarter (Nil both), so raw and underlying YoY PAT growth are identical.
Informational and educational content only. Not investment advice.